-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

158 Elranatamab, a BCMA Targeted T-Cell Engaging Bispecific Antibody, Induces Durable Clinical and Molecular Responses for Patients with Relapsed or Refractory Multiple Myeloma

Program: Oral and Poster Abstracts
Type: Oral
Session: 653. Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials: Bispecific Monoclonal Antibodies in Myeloma
Hematology Disease Topics & Pathways:
Research, clinical trials, Biological therapies, Bispecific Antibody Therapy, Clinical Research, Diseases, Therapies, Immunotherapy, Adverse Events, Minimal Residual Disease
Saturday, December 10, 2022: 12:15 PM

Noopur Raje, MD1, Nizar Jacques Bahlis, MD2, Caitlin Costello, MD3, Bhagirathbhai Dholaria, MBBS4, Melhem Solh, MD5, Moshe Yair Levy, MD6, Michael H Tomasson, MD7*, Michael A. Damore, PhD8*, Sibo Jiang, PhD9*, Cynthia Basu, PhD10*, Athanasia Skoura, PhD11*, Edward M Chan, MD12*, Suzanne Trudel13, Andrzej Jakubowiak, MD, PhD14*, Michael P Chu, MD15*, Cristina J. Gasparetto, MD16, Andrew P. Dalovisio, MD17, Michael Sebag, MD, PhD18 and Alexander M Lesokhin, MD19

1Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
2Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, AB, Canada
3Moores Cancer Center, University of California San Diego, La Jolla, CA
4Vanderbilt University Medical Center and Vanderbilt- Ingram Cancer Center, Nashville, TN
5Blood and Marrow Transplant Group of Georgia, Northside Hospital, Atlanta, GA
6Department of Medical Oncology, Baylor Scott and White Health, Dallas, TX
7Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA
8Oncology Research and Development, Pfizer, San Diego, CA
9Early Clinical Development, Pfizer Inc, San Diego, CA
10Early Clinical Development, Pfizer, San Diego, CA
11Early Clinical Development, Pfizer, Collegeville, PA
12Oncology Research and Development, Pfizer, South San Francisco, CA
13Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
14Department of Medicine, University of Chicago Medical Center, Chicago, IL
15Cross Cancer Institute, Edmonton, AB, Canada
16Department of Medicine, Duke University Cancer Institute, Durham, NC
17Department of Hematology and Oncology, Ochsner Health, Jefferson, LA
18Cedars Cancer Center, McGill University Health Centre, Montreal, QC, Canada
19Division of Hematology and Oncology, Memorial Sloan Kettering Cancer Center/Weill Cornell Medical College, New York, NY

Introduction: Multiple myeloma (MM) is a plasma cell dyscrasia characterized by expression of B-cell maturation antigen (BCMA). Elranatamab (PF-06863135), a bispecific antibody that targets BCMA and CD3 on T-cells, activates and redirects the T-cell mediated immune response against MM. This clinical trial, MagnetisMM-1 (NCT03269136), is the ongoing Phase 1 first-in-human study evaluating the safety, pharmacokinetics (PK), pharmacodynamics, and efficacy of elranatamab for patients (pts) with relapsed or refractory MM.

Methods: Elranatamab was administered subcutaneously (SC) at doses from 80 to 1000µg/kg either weekly or every 2 weeks. Treatment-emergent adverse events (TEAEs) were graded by National Cancer Institute Common Terminology Criteria for Adverse Events (v4.03), whereas cytokine release syndrome (CRS) was assessed by criteria of the American Society for Transplantation and Cellular Therapy. PK, cytokines, lymphocyte subsets, and soluble BCMA were analyzed over time. Clinical response was assessed by criteria of the International Myeloma Working Group (IMWG). Minimal residual disease (MRD) was assessed by next generation sequencing at a sensitivity of 1×10-5 in accordance with IMWG criteria.

Results: A total of 55 pts received single-agent elranatamab SC at a dose ≥215μg/kg as of 22-Jun-2022. Median age was 64 (range 42-80) years, and 27% of pts were Black/African American or Asian. Median number of prior regimens was 5 (range 2-14), 91% were triple-class refractory, 69% had prior stem cell transplantation, 29% had high cytogenetic risk, and 24% received prior BCMA-targeted therapy. The most common TEAEs regardless of causality included CRS, neutropenia, anemia, injection site reaction, and lymphopenia. With pre-medication and a single priming dose (600µg/kg or 44mg), the overall incidence of CRS at the recommended dose (1000µg/kg or 76mg) was 67% and limited to Grade 1 (33%) or Grade 2 (33%), with no events Grade 3 or higher. Elranatamab exposure was dose dependent. Cytokine increases occurred with the first dose and were reduced by pre-medication. Soluble BCMA decreased with disease response, elranatamab therapy was associated with increased peripheral T-cell proliferation, and median time to response was 36 days (range 7-262). With a median follow-up of 12.0 months (range 0.3-29.0) and including only IMWG confirmed responses, the objective response rate (ORR) was 64% (95% CI 50-75%) with 56% of pts (31/55) achieving very good partial response (VGPR) or better and 38% of pts (21/55) achieving complete response (CR) or better. Among 13 pts with prior BCMA-directed therapy (antibody drug conjugate, chimeric antigen receptor T-cell therapy, or both), 54% (7/13) achieved response including 46% (6/13) with VGPR or better. For responders (n=35), the probability of being event-free at 12 months was 59% (95% CI 39-74%) and the Kaplan-Meier estimate for median duration of response was 17.1 months (95% CI 10.6-NE). Single-agent elranatamab induced durable clinical and molecular responses, and 100% (12/12) of evaluable pts with confirmed CR or better achieved MRD negativity at a sensitivity of 1×10-5 including 2 pts with MRD negativity and ongoing stringent CR beyond 2 years.

Conclusions: Elranatamab induced durable clinical and molecular responses for pts with relapsed or refractory MM. The ORR was 64% with more than half of these pts (38%) achieving CR or better, and 100% of evaluable pts achieved MRD negativity. Together with emerging data from pivotal studies MagnetisMM-3 (NCT0469359) and MagnetisMM-5 (NCT05020236), these results support further development of elranatamab for patients with MM.

Disclosures: Raje: Bristol Myers Squibb: Consultancy, Honoraria; Research to Practice: Honoraria; Medscape: Honoraria; Amgen: Consultancy, Honoraria; Two Seventy Bio: Research Funding; Massachusetts General Hospita: Current Employment; Celgene: Honoraria; Janssen: Consultancy, Honoraria. Bahlis: Celgene: Consultancy, Honoraria; Takeda: Consultancy; Karyopharm Therapeutics: Consultancy, Honoraria; Janssen: Consultancy, Honoraria, Research Funding; GSK: Consultancy, Other; Sanofi: Consultancy, Honoraria; Genentech: Consultancy; Forus: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria, Research Funding; AbbVie: Consultancy, Honoraria; Amgen: Consultancy, Honoraria. Costello: BMS, Takeda, Janssen, Pfizer: Consultancy, Honoraria, Research Funding. Dholaria: Jazz Pharmaceuticals: Consultancy; Wugen: Research Funding; MEI Pharma: Research Funding; Vanderbilt University Medical Center: Current Employment; Gamida Cell: Consultancy; Angiocrine: Research Funding; MJH Biosciences: Honoraria; BMS: Research Funding; Orca Bio: Research Funding; Arivan: Consultancy; Molecular Templates: Research Funding; Poseida: Research Funding; Takeda: Research Funding; Pfizer: Research Funding; Janssen: Research Funding; BEAM Therapeutics: Consultancy. Solh: ADC Therapeutics: Research Funding; Partner Therapeutics: Research Funding. Levy: Epizyme: Honoraria, Speakers Bureau; BeiGene: Honoraria, Speakers Bureau; AstraZeneca: Honoraria, Speakers Bureau; Takeda: Consultancy, Honoraria, Speakers Bureau; Seagen: Honoraria, Speakers Bureau; Morphosys: Honoraria, Speakers Bureau; Karyopharm: Honoraria, Speakers Bureau; Janssen: Consultancy, Honoraria, Speakers Bureau; Baylor University Medical Center: Current Employment; GSK: Honoraria, Speakers Bureau; Gilead: Consultancy, Honoraria, Speakers Bureau; BMS: Consultancy, Honoraria, Speakers Bureau; Dova: Honoraria, Speakers Bureau; Abbvie: Consultancy, Honoraria, Speakers Bureau; Amgen: Consultancy, Honoraria, Speakers Bureau; Novartis: Honoraria, Speakers Bureau; TG Therapeutics: Honoraria, Speakers Bureau; Jazz Pharmaceuticals: Consultancy, Honoraria, Speakers Bureau; Sellas: Membership on an entity's Board of Directors or advisory committees; Sanofi: Honoraria, Speakers Bureau; Celgene: Consultancy; Seattle Genetics: Consultancy; Spectrum Pharmaceuticals: Consultancy. Damore: Pfizer: Current Employment, Current equity holder in publicly-traded company. Jiang: Pfizer: Current Employment, Current equity holder in publicly-traded company. Basu: Pfizer: Current Employment, Current equity holder in publicly-traded company. Skoura: Pfizer: Current Employment, Current equity holder in publicly-traded company. Chan: Pfizer: Current Employment, Current equity holder in publicly-traded company. Trudel: Karyopharm: Honoraria; AstraZeneca: Honoraria; Janssen: Honoraria, Research Funding; Forus: Consultancy; Sanofi: Honoraria; Genentech: Research Funding; Pfizer: Honoraria, Research Funding; Amgen: Consultancy, Honoraria, Research Funding; Roche: Consultancy, Honoraria, Research Funding; BMS: Consultancy, Honoraria, Research Funding; GlaxoSmithKline: Consultancy, Honoraria, Research Funding; Takeda: Honoraria. Jakubowiak: AbbVie: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; BMS: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; GSK: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Karyopharm Therapeutics: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Millennium: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Sanofi: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; SkylineDx: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Takeda: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees. Chu: Teva: Consultancy; Gilead: Consultancy; Celgene/BMS: Consultancy, Research Funding; Amgen: Consultancy; AstraZeneca: Consultancy; Janssen: Consultancy. Gasparetto: Sanofi: Honoraria, Other: TRAVEL, ACCOMMODATIONS, EXPENSES, Speakers Bureau; karyopharm: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: TRAVEL, ACCOMMODATIONS, EXPENSES, Speakers Bureau; Oncopeptides: Consultancy, Speakers Bureau; Celgene: Consultancy, Honoraria, Other: Travel expenses, Research Funding; Janssen: Consultancy, Honoraria; Takeda: Consultancy, Honoraria; AbbVie: Consultancy; GSK: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: TRAVEL, ACCOMMODATIONS, EXPENSES, Speakers Bureau; BMS: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Pfizer: Honoraria, Membership on an entity's Board of Directors or advisory committees. Sebag: BMS: Consultancy; Sanofi: Consultancy, Membership on an entity's Board of Directors or advisory committees; Pfizer: Membership on an entity's Board of Directors or advisory committees; Karyopharm: Consultancy, Membership on an entity's Board of Directors or advisory committees; Kite-Gilead: Membership on an entity's Board of Directors or advisory committees; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees; Celgene: Membership on an entity's Board of Directors or advisory committees; Takeda: Consultancy, Membership on an entity's Board of Directors or advisory committees; Amgen: Consultancy, Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees, Research Funding. Lesokhin: BMS: Honoraria; Sanofi: Research Funding; Trillium Therapeutics: Consultancy, Research Funding; Serametrix, inc: Patents & Royalties; Memorial Sloan Kettering Cancer Center: Current Employment; Pfizer, Genmab, Sanofi, Iteos, BMS, Janssen: Consultancy; Amgen: Honoraria; Janssen, Pfizer, BMS, Genentech/Roche: Research Funding; Janssen, Pfizer, Iteos, Sanofi, Genmab: Honoraria.

*signifies non-member of ASH